NCT03929068View on ClinicalTrials.gov

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

July 8, 2022

Study Completion Date

July 8, 2022

Conditions
Amyotrophic Lateral SclerosisMotor Neuron Disease
Interventions
DRUG

carbidopa-levodopa

Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.

DRUG

Placebo Oral Tablet

Placebo will be given to maintain blinding of participants and study team.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT03929068 - Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis | Biotech Hunter | Biotech Hunter